SCHEMBL27011880

SCHEMBL27011880

c1cc(-c2cccc3c4ccc5oc6ccccc6c5c4c4ccccc4c23)cc(N(c2cccc3ccccc23)c2cccc3ccccc23)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 2/20 0.35
▸ TDP1 Q9NUW8 1/20 0.35
▸ CYP1A1 P04798 2/20 0.34
▸ CYP1A2 P05177 2/20 0.34
▸ CYP1B1 Q16678 1/20 0.34
▸ AHR P35869 2/20 0.32
▸ FYN P06241 1/20 0.32
▸ MAPK3 P27361 1/20 0.32
▸ PAX8 Q06710 1/20 0.32
▸ ABCG2 Q9UNQ0 1/20 0.32
▸ ALOX5 P09917 1/20 0.32
▸ CASP3 P42574 1/20 0.31
▸ SENP7 Q9BQF6 1/20 0.31
▸ SENP6 Q9GZR1 1/20 0.31
▸ HCRTR1 O43613 1/20 0.31
▸ ALDH1A1 P00352 3/20 0.31
▸ MAPT P10636 3/20 0.31
▸ HPGD P15428 3/20 0.31
▸ HSD17B10 Q99714 3/20 0.31
▸ TSHR P16473 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24539728 0.96 CYP1A1 (0.32) L3MBTL1TDP1CYP1A1CYP1A2CYP1B1
SCHEMBL24539744 0.95 ABCG2 (0.33) L3MBTL1TDP1CYP1A1CYP1A2CYP1B1
SCHEMBL24539758 0.94 CYP1A1 (0.33) L3MBTL1TDP1CYP1A1CYP1A2CYP1B1
SCHEMBL24539731 0.92 CYP1A1 (0.32) L3MBTL1TDP1CYP1A1CYP1A2CYP1B1
SCHEMBL24539738 0.92 CYP1A1 (0.32) L3MBTL1TDP1CYP1A1CYP1A2CYP1B1
SCHEMBL27011995 0.91 CYP1A1 (0.32) L3MBTL1TDP1CYP1A1CYP1A2CYP1B1
SCHEMBL24539819 0.89 PLA2G2A (0.33) L3MBTL1TDP1CYP1A1CYP1A2CYP1B1
SCHEMBL27011391 0.88 PLA2G2A (0.34) L3MBTL1TDP1CYP1A1CYP1A2CYP1B1
SCHEMBL24540116 0.88 TDP1 (0.35) L3MBTL1TDP1CYP1A1CYP1A2CYP1B1
SCHEMBL27011148 0.88 CASP3 (0.36) L3MBTL1TDP1CYP1A1CYP1A2CYP1B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240023432-A1 HETEROCYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME, MANUFACTURING METHOD THEREFOR, AND COMPOSITION FOR ORGANIC LAYER LT MATERIALS CO., LTD. (KR) 2024-01-18 — — US disclosed
US-20240023432-A1 HETEROCYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME, MANUFACTURING METHOD THEREFOR, AND COMPOSITION FOR ORGANIC LAYER LT MATERIALS CO., LTD. (KR) 2024-01-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240023432-A1 HETEROCYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME, MANUFACTURING METHOD THEREFOR, AND COMPOSITION FOR ORGANIC LAYER CYP1B1, NOTUM, CYP4F11 L3MBTL1 1277/4885TDP1 1330/4885CYP1A1 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback